• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tao Synergies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8/6/25 9:21:13 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAOX alert in real time by email
    false 0001571934 0001571934 2025-08-06 2025-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 6, 2025

     

    TAO Synergies Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40458   46-1585656
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    1185 Avenue of the Americas, 3rd Floor
    New York, New York 10036
    (Address of principal executive offices and zip code)

     

    Registrant’s telephone number, including area code: (973) 242-0005

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange on which
    registered
    Common Stock, $0.0001 par value per share   TAOX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company. x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 7.01. Regulation FD.

     

    On August 6, 2025, TAO Synergies Inc. (the “Company”) issued a press release announcing its acquisition of TAO tokens as part of its digital asset treasury strategy directed toward TAO. A copy of the press release is attached as Exhibit 99.1 hereto.

     

    The information in this Item 7.01 to this Current Report on Form 8-K, and in Exhibit 99.1 furnished herewith, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

     

    Item 8.01. Other Events.

     

    On August 6, 2025, the Company announced aggregate purchases to date of 42,111 TAO tokens.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Description
    99.1 Press Release dated August 6, 2025
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    TAO SYNERGIES INC.

     

    Date: August 6, 2025 By: /s/ Robert Weinstein
      Name: Robert Weinstein
      Title: Chief Financial Officer

     

     

    Get the next $TAOX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TAOX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TAOX
    SEC Filings

    View All

    SEC Form S-8 filed by Tao Synergies Inc.

    S-8 - TAO Synergies Inc. (0001571934) (Filer)

    8/14/25 4:51:57 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Tao Synergies Inc.

    S-3 - TAO Synergies Inc. (0001571934) (Filer)

    8/14/25 4:50:01 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Tao Synergies Inc.

    10-Q - TAO Synergies Inc. (0001571934) (Filer)

    8/14/25 4:19:26 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TAO Synergies Accelerates Decentralized AI Treasury Strategy with 42,111 Bittensor (TAO) Tokens Acquired and Earned Through Staking to Date

    Largest publicly traded TAO pure-play treasury company TAO treasury strategy anchored at intersection of decentralized AI and cryptocurrencies NEW YORK, Aug. 6, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced that, as of August 5th, 2025, it has accumulated 42,111 Bittensor (TAO) tokens to date as part of its differentiated digital asset treasury strategy. "Our TAO-focused crypto strategy is anchored at the intersection of decentralized AI and blockchain," stated TAO Synergies' Executive Chairman Joshua Silverman. "In

    8/6/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TAO Synergies Acquires $10 Million of Bittensor (TAO) to Become Largest Publicly Traded Pure Play TAO Holder

    29,899 TAO tokens purchased to date Stakes tokens in decentralized AI network for yield generation NEW YORK, July 17, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (AI), today announced that as of July 17, 2025, it has acquired 29,899 TAO tokens for a total purchase price of $10.0 million, at an average price of approximately $334 per token. The purchases of TAO are in accordance with the Company's digital asset treasury strategy directed toward TAO, the native token for Bittensor, a decentralized AI network that incentivizes the development

    7/17/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    Financials

    Live finance-specific insights

    View All

    TAO Synergies Acquires $10 Million of Bittensor (TAO) to Become Largest Publicly Traded Pure Play TAO Holder

    29,899 TAO tokens purchased to date Stakes tokens in decentralized AI network for yield generation NEW YORK, July 17, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (AI), today announced that as of July 17, 2025, it has acquired 29,899 TAO tokens for a total purchase price of $10.0 million, at an average price of approximately $334 per token. The purchases of TAO are in accordance with the Company's digital asset treasury strategy directed toward TAO, the native token for Bittensor, a decentralized AI network that incentivizes the development

    7/17/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care